These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37479568)

  • 1. Elevated ApoE, ApoJ and lipoprotein-bound α-synuclein levels in cerebrospinal fluid from Parkinson's disease patients - Validation in the BioFIND cohort.
    Paslawski W; Svenningsson P
    Parkinsonism Relat Disord; 2023 Nov; 116():105765. PubMed ID: 37479568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients.
    Paslawski W; Zareba-Paslawska J; Zhang X; Hölzl K; Wadensten H; Shariatgorji M; Janelidze S; Hansson O; Forsgren L; Andrén PE; Svenningsson P
    Proc Natl Acad Sci U S A; 2019 Jul; 116(30):15226-15235. PubMed ID: 31270237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease.
    Ibanez L; Bahena JA; Yang C; Dube U; Farias FHG; Budde JP; Bergmann K; Brenner-Webster C; Morris JC; Perrin RJ; Cairns NJ; O'Donnell J; Álvarez I; Diez-Fairen M; Aguilar M; Miller R; Davis AA; Pastor P; Kotzbauer P; Campbell MC; Perlmutter JS; Rhinn H; Harari O; Cruchaga C; Benitez BA
    Acta Neuropathol Commun; 2020 Nov; 8(1):196. PubMed ID: 33213513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
    Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predominant apolipoprotein J exists as lipid-poor mixtures in cerebrospinal fluid.
    Suzuki T; Tozuka M; Kazuyoshi Y; Sugano M; Nakabayashi T; Okumura N; Hidaka H; Katsuyama T; Higuchi K
    Ann Clin Lab Sci; 2002; 32(4):369-76. PubMed ID: 12458888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease.
    Kang UJ; Boehme AK; Fairfoul G; Shahnawaz M; Ma TC; Hutten SJ; Green A; Soto C
    Mov Disord; 2019 Apr; 34(4):536-544. PubMed ID: 30840785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Apolipoproteins and α-Synuclein in Parkinson's Disease.
    Emamzadeh FN
    J Mol Neurosci; 2017 Aug; 62(3-4):344-355. PubMed ID: 28695482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.
    Akhtar RS; Licata JP; Luk KC; Shaw LM; Trojanowski JQ; Lee VM
    J Neurochem; 2018 Jun; 145(6):489-503. PubMed ID: 29500813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.
    Horvath I; Iashchishyn IA; Forsgren L; Morozova-Roche LA
    ACS Chem Neurosci; 2017 Jun; 8(6):1170-1176. PubMed ID: 28263550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma.
    Koch M; Furtado JD; Falk K; Leypoldt F; Mukamal KJ; Jensen MK
    Alzheimers Dement (Amst); 2017; 6():182-187. PubMed ID: 28289700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
    Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid α-synuclein seed assay of Parkinson's disease CSF panel shows high diagnostic accuracy.
    Orrù CD; Ma TC; Hughson AG; Groveman BR; Srivastava A; Galasko D; Angers R; Downey P; Crawford K; Hutten SJ; Kang UJ; Caughey B
    Ann Clin Transl Neurol; 2021 Feb; 8(2):374-384. PubMed ID: 33373501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Synuclein Interacts with Lipoproteins in Plasma.
    Emamzadeh FN; Allsop D
    J Mol Neurosci; 2017 Oct; 63(2):165-172. PubMed ID: 28887769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease.
    Yang Y; Keene CD; Peskind ER; Galasko DR; Hu SC; Cudaback E; Wilson AM; Li G; Yu CE; Montine KS; Zhang J; Baird GS; Hyman BT; Montine TJ
    J Neuropathol Exp Neurol; 2015 Jul; 74(7):672-87. PubMed ID: 26083568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.
    van Dijk KD; Bidinosti M; Weiss A; Raijmakers P; Berendse HW; van de Berg WD
    Eur J Neurol; 2014 Mar; 21(3):388-94. PubMed ID: 23631635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Majbour NK; Abdi IY; Dakna M; Wicke T; Lang E; Ali Moussa HY; Thomas MA; Trenkwalder C; Safieh-Garabedian B; Tokuda T; Mollenhauer B; El-Agnaf O
    Mov Disord; 2021 Sep; 36(9):2048-2056. PubMed ID: 33978256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.